高级检索
    胡晓云, 陈锦章, 王森锐. 阿替利珠单抗联合贝伐珠单抗与索拉非尼应用于不可切除肝细胞癌的疗效对比[J]. 循证医学, 2021, 21(6): 325-328. DOI: 10.12019/j.issn.1671-5144.2021.06.002
    引用本文: 胡晓云, 陈锦章, 王森锐. 阿替利珠单抗联合贝伐珠单抗与索拉非尼应用于不可切除肝细胞癌的疗效对比[J]. 循证医学, 2021, 21(6): 325-328. DOI: 10.12019/j.issn.1671-5144.2021.06.002
    shu
    HU Xiao-yun, CHEN Jin-zhang, WANG Sen-rui. Efficacy Comparison Between Atezolizumab Plus Bevacizumab and Sorafenib in Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 325-328. DOI: 10.12019/j.issn.1671-5144.2021.06.002
    Citation: HU Xiao-yun, CHEN Jin-zhang, WANG Sen-rui. Efficacy Comparison Between Atezolizumab Plus Bevacizumab and Sorafenib in Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 325-328. DOI: 10.12019/j.issn.1671-5144.2021.06.002
    shu

    阿替利珠单抗联合贝伐珠单抗与索拉非尼应用于不可切除肝细胞癌的疗效对比

    Efficacy Comparison Between Atezolizumab Plus Bevacizumab and Sorafenib in Unresectable Hepatocellular Carcinoma

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回